Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder
- 1 November 2016
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 26 (9) , 798-806
Abstract
Objectives: This naturalistic, retrospective study investigated the effects of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD) symptoms and autistic features in children with autism spectrum disorders (ASDs) and intellectual disability (ID). Methods: Participants (n = 37, age range 6–17 years, mean: 10.16 ± 3.60) were assessed at baseline, 4th and 12th weeks using Clinical Global Impressions (CGI) scales, DSM-IV-based ADHD-rating scale (ADHD-RS), and amended Turkish version of Aberrant Behavior Checklist (ABC). The primary outcome measure was a treatment response defined by a CGI-improvement score of 1 or 2 together with a decrease of at least 25% in the parent-rated ADHD-RS total score at the end of 12th week. Results: Five patients (13.5%) stopped medication at 4 weeks due to ineffectivity (2) and intolerable side effects (increased motor activity and talkativeness [n = 1], irritability [n = 2], temper outbursts [n = 2], and increased blood pressure [n = 1]). Sixteen patients (43.2%) were judged to be responders according to primary outcome measure. Improvement rate on CGI scale was 48.8%. On ADHD-RS, there were significant reductions between baseline and 4th week and between baseline and 12th week in both hyperactivity and inattention, and between baseline and 12th week in impulsivity scores. Decrease was significant in hyperactivity and social withdrawal subscales of the parent-reported ABC. Responders based on primary outcome measure were not significantly different from nonresponders in terms of sociodemographic features or clinical parameters, including intellectual, language, autism symptom, and ADHD symptom levels. Conclusion: In this chart review, ATX appears to be safe and effective for social withdrawal and ADHD symptoms in children with ASD and ID.Keywords
This publication has 32 references indexed in Scilit:
- Response to atomoxetine in boys with high‐functioning autism spectrum disorders and attention deficit/hyperactivity disorderActa Paediatrica, 2011
- Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum DisordersChild and Adolescent Psychiatric Clinics of North America, 2008
- Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacyChild and Adolescent Psychiatry and Mental Health, 2008
- The impact of analytic method on interpretation of outcomes in longitudinal clinical trialsInternational Journal Of Clinical Practice, 2008
- Norepinephrine Transporter Blockade With Atomoxetine Induces Hypertension in Patients With Impaired Autonomic FunctionHypertension, 2007
- Medication Use Among Children with Autism Spectrum DisordersJournal of Child and Adolescent Psychopharmacology, 2007
- Attention Deficit Hyperactivity Disorder Symptoms in Pervasive Developmental Disorders: Association with Autistic Behavior Domains and Coexisting PsychopathologyPsychopathology, 2007
- Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot StudyJournal of Child and Adolescent Psychopharmacology, 2006
- Open-Label Atomoxetine for Attention-Deficit/ Hyperactivity Disorder Symptoms Associated with High-Functioning Pervasive Developmental DisordersJournal of Child and Adolescent Psychopharmacology, 2006
- Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental DisordersJournal of Child and Adolescent Psychopharmacology, 2005